Insufficient evidence regarding benefits from sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction

Tatyana A. Shamliyan¹, Anna A. Avanesova², Wilbert S. Aronow³

¹Carvell Health Services, Inc, Cheltenham, PA 19012, USA.
²North-Caucasus Federal University, Stavropol 355000, Russian Federation.
³Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA.

Correspondence to: Dr. Tatyana A. Shamliyan, Carvell Health Services, Inc, Cheltenham, PA 19012, USA.
E-mail: sham1005@umn.edu

How to cite this article: Shamliyan TA, Avanesova AA, Aronow WS. Insufficient evidence regarding benefits from sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction. Vessel Plus 2020;4:35. http://dx.doi.org/10.20517/2574-1209.2020.34

Received: 27 Jul 2020 First Decision: 19 Oct 2020 Revised: 22 Oct 2020 Accepted: 28 Oct 2020 Published: 18 Nov 2020

Abstract

Aim: Sodium-glucose cotransporter-2 (SGLT2)-inhibitors improve survival in adults with reduced ejection fraction. Clinical outcomes in adults with heart failure (HF) with preserved ejection fraction (HFpEF) have not been systematically reviewed.

Methods: We conducted a systematic rapid literature review and appraised the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation methodology.

Results: We identified post-hoc subgroup analyses of four randomized controlled clinical trials (RCTs) and unpublished results from 2 RCTs vs. placebo, Canagliflozin reduced the risk of fatal or hospitalized HF in adults with HF and documented or assumed left ventricular ejection fraction (LVEF) ≥ 50% (hazard rate ratio, HR = 0.71, 95%CI: 0.52-0.97) but had no effect in a subpopulation with documented LVEF ≥ 50% (HR = 0.83, 95%CI: 0.55-1.25). Dapagliflozin or ertugliflozin did not improve all-cause or cardiovascular death or hospitalization for HF in adults with HF and LVEF > 45% in two pivotal RCTs vs. placebo. Empagliflozin did not improve exercise ability, patient-reported outcomes or congestion, diuretic use and all-cause healthcare resource utilization in unpublished RCT vs. placebo. Various definitions of HFpEF, post-hoc interaction analyses suggesting outcome improvement...
regardless of heart failure type, small number of events, and probable publication bias hampered the quality of evidence.

**Conclusion:** Existing evidence is insufficient to support definitive clinical recommendations for use of SGLT2-inhibitors in adults with HFpEF. Future research should employ consistent definitions of HFpEF and examine the effects from SGLT2-Inhibitors in patients with various HFpEF phenotypes and underlying causes.

**Keywords:** Sodium-glucose cotransporter-2 - inhibitors, heart failure with preserved ejection fraction, cardiovascular mortality, heart failure hospitalization, systematic literature review, grading of recommendations assessment, development and evaluation methodology

**INTRODUCTION**

Heart failure with preserved ejection fraction (HFpEF) presents a significant and growing clinical and economic burden in aging populations, specifically with prevalent arterial hypertension and diabetes\(^1\)-\(^4\). Estimated 1-year all-cause mortality rates of 33\% and all cause readmission rates of 67\% in patients with HFpEF have not improve over the last decade in the US\(^3\). Diabetes is a widely recognized risk factor for cardiovascular morbidity and mortality\(^5\)-\(^6\). Although emerging treatments improved cardiovascular outcomes in people with diabetes\(^7\)-\(^8\), no treatments have been proven to improve survival and reduce health care utilization in people with HFpEF\(^5\)-\(^8\). Sodium-glucose cotransporter-2 (SGLT2)-inhibitors are found to improve survival in heart failure with reduce ejection fraction and reduce the risk of major cardiovascular events including heart failure hospitalizations in adults with type 2 diabetes\(^1\)-\(^4\). Empagliflozin and canagliflozin have been approved by the US Food and Drug Administration (FDA) to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease while dapagliflozin has also been approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with reduced left ventricular ejection fraction (LVEF ≤ 40\%)\(^9\)-\(^14\). Recent evidence-based guidelines recommend SGLT2- inhibitors for the improvement in cardiovascular outcomes in adults with type 2 diabetes\(^15\)-\(^19\). However, the evidence regarding the benefits from SGLT2- inhibitors in adults with HFpEF has not been systematically reviewed and appraised. We conducted a systematic rapid literature review of all completed and ongoing clinical studies aimed at patient outcomes in adults with HFpEF.

**METHODS**

We conducted our review according to the developed priori protocol\(^20\)-\(^22\). We hypothesized that SGLT2-inhibitors improve cardiovascular mortality, morbidity and hospitalizations in adults with HFpEF, with or without diabetes\(^23\)-\(^26\).

Eligible interventions included SGLT2- inhibitors regardless of country’ approval [Supplementary Table 1] focusing on the availability in the US, for example dapagliflozin, canagliflozin, empagliflozin and ertugliflozin [Supplementary Table 2]. We included studies that compared SGLT2- inhibitors with antidiabetic medications or placebo. We abstracted reported number of events or rates of all-cause and cardiovascular mortality, incident or progressing of heart failure, and hospitalizations for heart failure\(^24\)-\(^26\). We also looked at the reported intermediate outcomes, e.g., exercise tolerability and the quality of life or other patient reported outcomes as defined in the primary studies\(^24\)-\(^45\).

We conducted a comprehensive search with MeSH terms and key words in PubMed, Scopus, the Cochrane Library, www.clinicaltrials.gov, the World Health organization International Clinical Trials Registry Platform, Health Technology Assessment databases, and regulatory agencies up to October 2020 to find
systematic reviews, published and unpublished randomized controlled clinical trials (RCTs), and real-world evidence from the high quality nationally representative controlled observational studies\[^{[30,31]}\]. All of the authors looked at the retrieved publications as well as the evidence-based guidelines that provided definitions of HFpEF and recommend treatments for HFpEF. We documented the eligibility of studies in a reference database.

We planned a quantitative direct meta-analysis of similar interventions and outcomes using random effects models in compliance with recommended meta-analytic methods\[^{[46]}\]. We intended to calculate pooled relative risk, absolute risk difference, number needed to treat and number of attributable events per 1000 treated with 95% confidence intervals (CI). We proposed to examine inconsistency in treatment effects with recommended I\(^2\) statistics (if I\(^2\) was > 50%)\[^{[30]}\]. We planned pooled analyses regardless of statistically significant heterogeneity\[^{[46]}\]. Instead, we proposed exploring heterogeneity with a prior defined patient characteristics, e.g., definitions of HFpEF, outcomes, and study quality\[^{[46]}\].

Since post hoc analyses of statistical power is not recommended\[^{[47-56]}\], we downgraded the quality of evidence for imprecision based on an estimated priori optimal information size in an adequately powered RCT (e.g., ≥ 250 patients with the event)\[^{[51]}\].

We concluded statistical significance at a 95% confidence level using Statistics/Data Analysis, STATA software (StataCorp LP, College Station, Texas).

We judged the risk of bias in primary studies with the Cochrane risk of bias tool\[^{[52-54]}\]. We judged the quality of evidence according to the recommendations by the grading of recommendations assessment, development and evaluation (GRADE) methodology\[^{[55]}\]. We downgraded the quality of evidence from RCTs according to the domains of the risk of bias in the body of evidence, directness of comparisons, precision and consistency in treatment effects, and the probability of the reporting bias\[^{[55]}\]. We assigned low quality of evidence to all nonrandomized studies, upgrading the quality for the evidence of a strong or dose-response association\[^{[56]}\]. We concluded insufficient evidence when valid information about treatment effects was not identified.

**RESULTS**

We excluded the majority of clinical studies of SGLT2- inhibitors because they did not report patient outcomes in adults with HFpEF (search strings are available in the appendix and the list of excluded publications and registered studies is available by the request from the authors). We identified post hoc subgroup individual patient data meta-analysis of the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program that examined canagliflozin when compared with placebo in patients with HFpEF \[^{[57]}\]. We identified post-hoc subgroup analysis of the pivotal DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) RCT that examined dapagliflozin when compared with placebo in patients with HFpEF \[^{[58]}\]. We also identified unpublished results from pivotal EMPIERIAL trials that examined empagliflozin when compared with placebo in patients with HFpEF\[^{[59-61]}\]. We identified post-hoc subgroup analysis of the pivotal VERTIS CV RCT (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial) that examined ertugliflozin when compared with placebo in patients with HFpEF \[^{[62]}\].

We did not identify observational studies that reported patient outcomes after SGLT2- inhibitors in patients with HFpEF and concluded probable publication bias because several completed registered studies remain unpublished. We downgraded the quality of evidence for high risk of bias in post-hoc subgroup analyses, imprecision in treatment effects due to small number of events, and probable publication bias. We concluded that the evidence is insufficient for definitive clinical recommendation to use SGLT2- inhibitors
for the reduction in cardiovascular mortality, morbidity or heart failure hospitalizations in patients with HFrEF.

**Canagliflozin**

Canagliflozin did not reduce the risk of fatal or hospitalized heart failure when compared with placebo in adults with type 2 diabetes and heart failure with documented LVEF of ≥ 50% [Table 1][57]. Canagliflozin reduced the risk of fatal or hospitalized heart failure in a subpopulation with heart failure and documented LVEF of ≥ 50% [Table 1][57].

The CANVAS RCTs did not examine LVEF at baseline in enrolled adults of ≥ 30 years of age with a history of symptomatic atherosclerotic cardiovascular disease or aged ≥ 50 years with 2 or more risk factors for cardiovascular disease[44,63]. Post hoc subgroup analysis was based on retrospective secondary review of the medical hospitalization record data by one of the members of the original adjudication committee who was blinded to individual participant treatment assignment; **Prospective baseline assessment of ejection fraction was conducted in all participants; **Ejection fraction was assessed from medical records when available. EF: ejection fraction; HR: hazard rate ratio

The authors conducted a sensitivity analysis assuming that patients with unknown LVEF had HFrEF (61 patients) and found a significant protective effects from canagliflozin in this combined subpopulation [57].

Based on post hoc interaction model and protective effects from canagliflozin in heart failure with reduced ejection fraction (LVEF < 50%), the authors concluded similar canagliflozin benefits in the overall trial population [57].

---

**Table 1. Sodium-glucose cotransporter 2 inhibitors in adults with heart failure with preserved ejection fraction, the results from post-hoc subgroup analyses of the randomized controlled clinical trials**

| Population Definition                                                                 | Outcome                                                                 | Treatment effect |
|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------|
| Canagliflozin vs. Placebo the CANVAS Program[^57^][^5^][^57^][^1^] ClinicalTrials.gov/NCT01032629/NCT01989754 | Heart failure event with documented EF of ≥ 50% at the HF admission    |                 |
|                                                        | Fatal or hospitalized heart failure                                     | HR 0.83 (0.55-1.25) |
| Canagliflozin vs. Placebo the CANVAS Program[^57^][^5^][^57^][^1^] ClinicalTrials.gov/NCT01730534 | Heart failure event with documented EF of ≥ 50% or assumed to be ≥ 50% |                 |
|                                                        | Fatal or hospitalized heart failure                                     | HR 0.71 (0.52-0.97) |
| Dapagliflozin, 10 mg vs. Placebo DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58)[^57^][^57^][^57^][^5^][^5^] ClinicalTrials.gov/NCT01730534 | Heart failure with EF of ≥ 45% or without known reduced ejection fraction |                 |
|                                                        | Cardiovascular death or hospitalization for heart failure               | HR 0.88 (0.66-1.17) |
|                                                        | Hospitalization for heart failure                                      | HR 0.72 (0.5-1.04)  |
|                                                        | Cardiovascular death                                                   | HR 1.41 (0.93-2.13) |
|                                                        | All-cause mortality                                                    | HR 1.02 (0.75-1.38) |
| Dapagliflozin, 10 mg vs. Placebo DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58)[^57^][^57^][^57^][^5^][^5^] ClinicalTrials.gov/NCT01730534 | Heart failure with EF of ≥ 45%                                         |                 |
|                                                        | Cardiovascular death or hospitalization for heart failure               | HR 0.79 (0.56-1.13)  |
|                                                        | Hospitalization for heart failure                                      | HR 0.74 (0.48-1.14)  |
|                                                        | Cardiovascular death                                                   | HR 1.44 (0.83-2.49)  |
|                                                        | All-cause mortality                                                    | HR 1.06 (0.71-1.59)  |
| Ertugliflozin, 5 mg, 15 mg vs. Placebo (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial)[^62^][^62^][^62^][^62^][^62^] ClinicalTrials.gov/NCT01986881 | Heart failure with EF > 45%                                            |                 |
|                                                        | Cardiovascular death or hospitalization for heart failure               | HR 0.92 (0.61-1.39)  |
|                                                        | Cardiovascular death                                                   | HR 1.08 (0.64-1.8)   |
|                                                        | All-cause mortality                                                    | HR 1.01 (0.66-1.56)  |
|                                                        | Hospitalization for heart failure                                      | HR 0.70 (0.39-1.26)  |

[^5]: Statistically significant differences at 95% confidence level. *Ejection fraction was assessed during retrospective secondary review of the medical record data by one of the members of the original adjudication committee who was blinded to individual participant treatment assignment; **Prospective baseline assessment of ejection fraction was conducted in all participants; ***Ejection fraction was assessed from medical records when available. EF: ejection fraction; HR: hazard rate ratio
Canagliflozin improved diastolic function in patients with type 2 diabetes in two Japanese non-randomized controlled clinical trials. One trial of canagliflozin in outpatients with chronic heart failure and diabetes (CANOSSA trial: prospective, open-label, add-on trial of canagliflozin for diabetes mellitus and stable chronic heart failure) enrolled 94% of patients with HFpEF (exact definition was not provided). Canagliflozin improved echocardiographic parameters of diastolic function at 6 and 12 month ($P < 0.001$). The second pilot study reported improved left ventricular diastolic function after 3 months of canagliflozin treatment although it did not specify baseline HFpEF.

**Dapagliflozin**

Dapagliflozin did not improve all-cause or cardiovascular death or hospitalization for heart failure in adults with type 2 diabetes and HFpEF (LVEF $\geq 45\%$) [Table 1].

DECLARE-TIMI 58 investigators conducted a prospective baseline assessment of ejection fraction in all enrolled patients with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD and with a creatinine clearance $\geq 60$ mL/min. The authors acknowledged the absence of universally accepted definitions of HFpEF and reported outcomes in subpopulations with various baseline LVEF thresholds ($< 45\%, \geq 45\%, \text{and}\ 45\%-55\%$). Based on post hoc interaction model and protective effects from dapagliflozin in heart failure with reduced ejection fraction, the authors concluded similar dapagliflozin benefits in overall trial population.

We identified two RCTs that examined the effects from dapagliflozin on diastolic function in adults with type 2 diabetes. The RCT enrolling patients with heart failure reported that dapagliflozin significantly improved diastolic function in those with baseline LVEF $\geq 45\%$. The second RCT that enrolled patients without prior history of heart failure, reported that dapagliflozin had no effect on diastolic function when compared with placebo.

Ongoing registered studies reported different definitions of HFpEF, exclusion of adults with various thresholds of reduced LVEF (e.g., $< 45\%$ or $< 50\%$) and various definitions of primary and secondary outcomes [Table 2]. Available protocols did not provide details on estimated statistical power and required sample size to detect statistically significant differences in primary outcomes.

**Empagliflozin**

Empagliflozin did not improve exercise tolerance, patient-reported outcomes related to the quality of life and patient satisfaction, congestion, diuretic use and all-cause healthcare resource utilization in adults with HFpEF enrolled in the pivotal EMPERIAL trials. Trials enrolled adults with heart failure with or without diabetes. The authors defined HFpEF as symptomatic heart failure with LVEF $> 40\%$ and elevated N-Terminal Pro-Brain Natriuretic Peptide [Table 3]. The unpublished results have been presented in the meeting of the European Society of Cardiology in June 2020. Some positive trends in improving congestion after empagliflozin in HFpEF did not achieve statistical significance, possibly due to insufficient statistical power.

The pivotal Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME Trial) did not examine baseline ejection fraction but reported improvement in diastolic dysfunction as a possible mechanism in the observed reduced cardiovascular mortality and morbidity.

Ongoing registered studies reported different definitions of HFpEF (e.g., LVEF $\geq 40$ or $\geq 50\%$), exclusion of adults with various thresholds of the reduced LVEF (e.g., $< 30\%$ or $< 40\%$) and various definitions of primary and secondary outcomes [Table 3]. Available protocols did not provide details on estimated statistical power and required sample size to detect statistically significant differences in primary outcomes.
Ertugliflozin

The ongoing evaluation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV) enrolled adults with type 2 diabetes and established atherosclerotic cardiovascular disease, did not specify subgroup analysis depending on baseline ejection fraction obtained from medical records but reported that 80.6% of 8,238 randomized patients had HFpEF (LVEF > 40%) \[69\]. This RCT was designed to determine non-inferiority of ertugliflozin when compared with placebo on major adverse CV events including death, nonfatal myocardial infarction, or nonfatal stroke \[69\]. Preliminary publications defined HFpEF as LVEF > 45% and reported no reduction in patient outcomes in this subpopulation after comparing ertugliflozin vs. placebo \[Table 1\]. Based on the post hoc interaction model and protective effects from ertugliflozin in heart failure with reduced ejection fraction, the authors concluded similar ertugliflozin benefits in the overall trial population \[62,70\].
| NCT number phase enrollment | Title acronym | Inclusion criteria defining HPREF | Exclusion by LVEF | Outcome measures |
|----------------------------|---------------|----------------------------------|-------------------|-----------------|
| NCT02932436 | Effects of Empagliflozin on left ventricular diastolic function compared to usual care in type 2 diabetics EmDia | Diastolic cardiac dysfunction E/E' ratio ≥ 8 NYHA classification III - IV | Change from baseline in E/E' ratio, Left end-diastolic volume (LEDV) |
| NCT03057951 | Empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction (EMPEROR-Preserved) | Symptomatic heart failure (NYHA class II-IV) LVEF > 40 % NT-proBNP > 300 pg/ml for patients without AF, OR > 900 pg/ml for patients with AF | Composite primary endpoint: CV death or hospitalization for heart failure failure); All hospitalizations for heart failure; All-cause mortality; Change from baseline in KCCQ; All-cause hospitalizations |
| NCT03448406 | Empagliflozin in Patients with chronic heart failure with preserved ejection fraction (EMPORER-Preserved) | 6MWT M 350 m Symptomatic heart failure (NYHA class II-IV) LVEF > 40% NT-proBNP > 300 pg/ml for patients without AF, OR > 600 pg/ml for patients with AF Prior LVEF M 40% | Change from baseline in: 6MWT, KCCQ TS, chronic heart failure questionnaire, self- administered standardized format (CHQ-SAS) dyspnea score, patient global impression of severity (PGI-S) of heart failure symptoms, patient global impression of dyspnea severity, patient general impression of change in NT-proBNP, Regional LV diastolic function |
| NCT02998970 | Effects of Empagliflozin on cardiac structure in patients with type 2 diabetes EMPA-HEART | Previous myocardial infarction ≥ 6 months ago, or previous coronary revascularization ≥ 2 months ago LVEF < 30% NYHA Class IV or recent hospitalization for decompensated heart failure (HF) Permanently atrial flutter or atrial fibrillation | Change from baseline in: Left Ventricular (LV) mass|LV end-diastolic volume|LVEF(Regional LV diastolic function |
| NCT03753087 | Effects of Empagliflozin on exercise capacity and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and Type-2 diabetes mellitus EMPERIAL-preserved | Symptoms 4 signs of heart failure (as defined in 2016 European society of cardiology guidelines) LVEF ≥ 50% LV diastolic dysfunction grade II/III | Change from baseline in: 6MWD|LVMI|left atrial volume index (LAVI)] average E/e' ratio|NT-proBNP|Minnesota living with heart failure questionnaire (MLHFQ) score |
| NCT03332212 | EMPA-VISION: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with heart failure EMPA-preserved | LVEF ≥ 50% as measured by ECHO structural heart disease NT-proBNP > 125 pg/mL in patient without AF or NT-proBNP > 600 pg/mL in patient with AF | Change from baseline in myocardial phosphocreatine-to-ATP ratio |
| CTRI/2017/09/009734 | Empagliflozin trial in patients with chronic heart failure EMPA-VISION: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with heart failure EMPA-VISION: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with heart failure | Chronic symptomatic heart failure (NYHA class II-IV) LVEF > 40% Elevated NT-proBNP > 300 pg/mL for patients without AF, OR > 900 pg/ml for patients with AF | The composite endpoint: CV death or hospitalization for heart failure failure; All-cause mortality; Change from baseline in clinical summary score of the KCCQ; All-cause hospitalizations |
| JPRN-jRCTs071180091 | Effect of empagliflozin for HPREF with Type2 DM A clinical study for cardioprotective effect of empagliflozin in T2DM patients with heart failure and exploring associated factors (EMPOWERMENT) | Symptomatic heart failure (NYHA class II-III) LVEF > 50% BNP > 35 pg/dL | Change from baseline in: uptake efficiency (Peak VO2) BNP LVFV and RVF(by MRI) |
Other SGLT2 inhibitors
Limited evidence from small unpublished Japanese RCTs suggested that luseogliflozin (63 patients), and tofogliflozin (62 patients) improved diastolic dysfunction from baseline in adults with diabetes and HFpEF[71]. However, luseogliflozin, when compared with voglibose, did not improve diastolic dysfunction or brain natriuretic peptide (BNP) levels in type 2 diabetes patients with HFpEF (defined as LVEF > 45% and BNP =35 pg/mL)[72].

We identified 60 registered studies of ipragliflozin, sotagliflozin, luseogliflozin, or tofogliflozin that did not report enrolling patients with HFpEF.

DISCUSSION
Our review found insufficient evidence that SGLT2 inhibitors can improve cardiovascular mortality, morbidity or hospitalizations in patients with HFpEF. We found no studies that reported adverse effects from SGLT2 inhibitors specifically in adults with HFpEF[73]. Limited evidence of some improvement in intermediate outcomes of diastolic dysfunction lack clinical significance with valid prediction of better patient-centered outcomes and healthcare utilization required in future studies[74,75]. The absence of RCTs that met pooling criteria precluded planned meta-analyses. Previously published indirect net-work meta-analyses focused on intermediate outcomes of diastolic dysfunction regardless of baseline HFpEF and did not find consistent superiority of SGLT2 inhibitors when compared with placebo or other anti-diabetic medications[74,75]. Previously published direct meta-analysis concluded that SGLT2 inhibitors reduced the risk of cardiovascular death or heart-failure hospitalization regardless of baseline heart failure diagnosis[15]. However, this meta-analysis did not look at patient outcomes depending on baseline LVEF and specifically in patients with HFpEF[15].

Various definitions of HFpEF preclude valid comparisons of patient outcomes among RCTs of the same SGLT2 inhibitor and across RCTs of different SGLT2 inhibitors [Supplementary Table 2][28,37,76-80]. Ongoing studies use various inclusion and exclusion criteria with a potential threat to external validity of completed in future studies[81]. Consistent consensus definition of HFpEF in guidelines, RCTs, and real life clinical practice and coding is essential for valid assessment of the best treatment options in adults with HFpEF[33,34,37,76-80]. Patient outcomes can differ depending on HFpEF diagnostic criteria and should be assessed by HFpEF phenotypes[38,79,80]. Subgroup analyses by HFpEF diagnostic criteria and phenotypes should be conducted with prespecified evidence-based definitions, stratified randomization and adequate sample size[86,87]. Known interactions between HFpEF phenotypes and treatment effects should guide future studies aimed at efficacious treatments[11,43]. Registered protocols of ongoing RCTs are inconsistent in addressing recommendations by guidelines hard clinical outcomes including all-cause and cardiovascular mortality, morbidity, hospitalizations, or quality of life in people with HFpEF[88,89]. Such inconsistency indicates that the most important clinical questions regarding the benefits from SGLT2 inhibitors on patient centered outcomes may not be answered in the upcoming years.

Available heart failure guidelines recommend SGLT2 inhibitors to reduce cardiovascular mortality and hospitalizations in patients with diabetes [Supplementary Table 3][5,26-28,89,90]. Some guidelines specify recommendations of SGLT2 inhibitors in heart failure with reduced ejection fraction[5,29]. Very few guidelines including the Canadian Cardiovascular Society and Canadian Heart Failure Society guidelines and the American Diabetes Association Standard of Care statement acknowledge uncertainty regarding potential benefits of SGLT2 inhibitors for patients with midrange or preserved LVEF[5,29]. Older guidelines do not make recommendations for or against SGLT2 inhibitors aimed at the prevention of heart failure hospitalizations or mortality[33,34,38,91].

We found no large observational studies of SGLT2 inhibitors in HFpEF. We can speculate that inconsistencies in diagnostic and treatment recommendations for patients with HFpEF preclude optimal treatment choices
in these patients\textsuperscript{[92,93]}\textsuperscript{[92,93]}. Diabetes care should be provided by multidisciplinary teams of endocrinologists, cardiologists and nephrologists and include assessment of HFrEF and consequent decisions of the best treatment choices\textsuperscript{[3,4,6,46]}\textsuperscript{[3,4,6,46]}.

Inconsistency in clinical research and practice policies, market approval, and coverage decisions across countries preclude universal patient access to the optimal treatment options\textsuperscript{[96-98]}\textsuperscript{[96-98]}. Harmonization of health technology assessments methodology and data sharing across the countries would improve the quality of care in patients with heart failure and specifically HFrEF\textsuperscript{[99,100]}\textsuperscript{[99,100]}. The International Network of Agencies for Health Technology Assessment calls for transparency in evidence collection, data sharing, and consistent evidence appraisal to improve patient outcomes across the globe\textsuperscript{[101]}\textsuperscript{[101]}.

Our work has implications for future research. The emerging epidemic of diabetes, arterial hypertension and HFrEF requires international efforts in improving the quality of evidence and the quality of healthcare\textsuperscript{[10,26,40]}\textsuperscript{[10,26,40]}. Professional associations and health technology assessment groups need to collaborate in the development of consensus definitions of HFrEF, in prospective design of high quality powered RCTs in adults with various phenotypes and underlying causes of HFrEF. Individual patient data meta-analyses of completed RCTs and registries of medical records can shed light on optimal treatment choices in adults with HFrEF\textsuperscript{[102-105]}\textsuperscript{[102-105]}.

In conclusion, existing evidence is insufficient to support definitive clinical recommendations for use of SGLT2- Inhibitors in adults with HFrEF. Future research should employ consistent definitions of HFrEF and examine the effects from SGLT2- Inhibitors in patients with various HFrEF phenotypes and underlying causes.

**DECLARATIONS**

**Authors' contributions**

Designed review protocol, research questions and performed data analysis and interpretation: Shamliyan TA

Conceptualized study objectives and goals and contributed to data analysis and interpretation: Aronow WS

Contributed to study design and execution, data analysis and interpretation: Avanesova AA

Made substantial contributions to the writing of the manuscript: Shamliyan TA, Avanesova AA, Aronow WS

**Availability of data and materials**

Not applicable.

**Financial support and sponsorship**

None.

**Conflicts of interest**

All authors declared that there are no conflicts of interest.

**Ethical approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Copyright**

© The Author(s) 2020.
REFERENCES

1. Shamliyan T, Nambiar S, Martin A. PCV63 what’s the cost of hospitalisations due to heart failure with preserved ejection fraction in the United States? Value Health 2019;22:5552-3.
2. Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2014;11:354-65.
3. Ziaeian B, Heidenreich PA, Xu H, et al. Race/ethnic differences in outcomes among hospitalized medicare patients with heart failure and preserved ejection fraction. JACC Heart Fail 2017;5:483-93.
4. Bouthoorn S, Valstar GB, Gohar A, et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diab Vasc Dis Res 2018;15:477-93.
5. American Diabetes Association Position Statement. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care 2020;43:S111-34.
6. American Diabetes Association Position Statement. 12. Older Adults: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S152-62.
7. Rawshani A, Rawshani A, Fransen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407-18.
8. Huy T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep 2019;21:45.
9. Borlau BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559-73.
10. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2013;10:401-10.
11. Zheng SL, Chan FT, Nabebeaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart (British Cardiac Society) 2018;104:407-15.
12. Kjeldsen SE, von Lueder TG, Smiseth OA, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension 2020;75:23-32.
13. Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Ann Rev Med 2018;69:65-79.
14. Bonsu KO, Arummanakul P, Chaiyakanapruk N. Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison. Heart Fail Rev 2018;23:147-56.
15. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 2019;393:31-9.
16. Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017;5:709-17.
17. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:1845-55.
18. Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol 2019;12:299-308.
19. Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail 2019;6:927-35.
20. AstraZeneca Pharmaceuticals LP Wilmington D. FARXIGA- dapagliflozin tablet, film coated FDA label. May 2020. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/0190c547-5471-4a1b-81f8-80048b850529b/spl-doc?hl=dapaglifozin. [Last accessed on 16 Nov 2020]
21. Boehringer Ingelheim Pharmaceuticals Inc. JARDIANCE- empagliflozin tablet, film coated FDA label. 2014. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/a77214ca-572e-485e-aae9-c7950187e5fb/spl-doc?hl=empaglifozin. [Last accessed on 16 Nov 2020]
22. Janssen Pharmaceuticals Inc. INVOKANA- canagliflozin tablet, film coated FDA label. March 2013. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/b9057d3b-b104-4b09-8a61-c61e9d4a3f3/spl-doc?hl=canaglifozin. [Last accessed on 16 Nov 2020]
23. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG outcome trial. Circulation 2019;139:1384-95.
24. Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 2018;138:458-68.
25. Dewan P, Solomon SD, Jhund PS, et al. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Eur J Heart Fail 2020;22:1247-58.
26. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140:e294-324.
27. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America. J Card Fail 2019;25:584-619.
28. Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol 2017;33:1342-433.
29. O’Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation,
SGLT2 inhibitors, ARNI in HFrEF, and tafamidis in amyloidosis. *Can J Cardiol* 2020;36:159-69.
30. Higgins J, Green S, editors. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. London: The Cochrane Collaboration; 2011. Available from: https://training.cochrane.org/handbook/current. [Last accessed on 16 Nov 2020]
31. Slutsky J, Atkins D, Chang S, Sharp BA. AHQR series paper 1: comparing medical interventions: AHQR and the effective health-care program. *J Clin Epidemiol* 2010;63:481-3
32. Polisena J, Garrity C, Kamel C, Stevens A, Abou-Setta AM. Rapid review programs to support health care and policy decision making: a descriptive analysis of processes and methods. *Syst Rev* 2015;4:1-7.
33. Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. *Circulation* 2013;128:e240-327.
34. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129-200.
35. Chow B, Rahkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. *Heart Fail Rev* 2015;20:291-303.
36. Machino-Ohtsuka T, Seo Y, Ishizu T, et al. Clinical utility of the 2016 ASE/EACVI recommendations for the evaluation of left ventricular diastolic function in the stratification of post-discharge prognosis in patients with acute heart failure. *Eur heart J Cardiovasc Imaging* 2019;20:1129-37.
37. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr* 2016;29:277-314.
38. Lindman BR, Davila-Roman VG, Mann DL, et al. Cardiovascular phenotype in HFrEF patients with or without diabetes: a RELAX trial ancillary study. *J Am Coll Cardiol* 2014;64:541-9.
39. Greene SJ, Mentz RJ, Fuzziat M, et al. Reassessing the role of surrogate end points in drug development for heart failure. *Circulation* 2018;138:1039-53.
40. Lekavich CL, Barksdale DJ, Neelon V, Wu JR. Heart failure preserved ejection fraction (HFrEF): an integrated and strategic review. *Heart Fail Rev* 2015;20:643-53.
41. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). *Cardiovasc Diabetol* 2014;13:102.
42. Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 Trial. *Am Heart J* 2018;200:83-9.
43. Riddlerstrale M, Svard E, Zeller C, Kim G, Woerder HJ, Broedel UC. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. *Cardiovasc Diabetol* 2013;12:129.
44. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. *Am Heart J* 2013;166:217-23.e11.
45. Abraham WT, Ponikowski P, Brueckmann M, et al. Rationale and design of the EMPERIAL-preserved and EMPERIAL-reduced trials of empagliflozin in patients with chronic heart failure. *Eur J Heart Fail* 2019;21:932-42.
46. Fu R, Gantlechner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHQR and the effective health care program. *J Clin Epidemiol* 2011;64:1187-97.
47. Levine M, Ensom MH. Post hoc power analysis: an idea whose time has passed? *Pharmacotherapy* 2001;21:405-9.
48. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. *Ann Intern Med* 1994;121:200-6.
49. Yuan KH, Maxwell S. On the post hoc power in testing mean differences. *J Educ Behav Stat* 2005;30:141-67.
50. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHQR Publication No 10(14)-EHC063-EF. 2014. Rockville, MD. Available from: https://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. [Last accessed on 16 Nov 2020]
51. Shamliyan et al. Vessel Plus 2020;4:35 | http://dx.doi.org/10.20517/2574-1209.2020.34 Page 11 of 13
58. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. *Circulation* 2019;139:e2528-36.
59. Ponikowski P, Abraham W. Favourable effects of empagliflozin on congestion, diuretic use and all-cause healthcare resource utilisation in the EMPERIAL trials. *European Society of Cardiology* 365. 2020; HFA Discoveries. Available from: https://esc365.escardio.org/Congress/223730-favourable-effects-of-empagliflozin-on-congestion-diuretic-use-and-all-cause-healthcare-resource-utilisation-in-the-emperial-trials. [Last accessed on 16 Nov 2020]
60. Lindenfeld J. Patient-reported outcomes with empagliflozin in the EMPERIAL trials. *European Society of Cardiology* 365. 2020; HFA Discoveries. Available from: https://esc365.escardio.org/Congress/223722-patient-reported-outcomes-with-empagliflozin-in-the-emperial-trials. [Last accessed on 16 Nov 2020]
61. Boehringer Ingelheim. Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure. 2019. Available from: https://www.boehringer-ingelheimus/press-release/boehringer-ingelheim-and-lilly-provide-update-jardiance-phase-iii-exercise-ability. [Last accessed on 16 Nov 2020]
62. Cosentino F, Cannon CP, Charytan DZ, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. *Circulation* 2020; doi: 10.1161/CIRCULATIONAHA.120.050255.
63. Mahaffey KW, Neil B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). *Circulation* 2018;137:323-34.
64. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. *Cardiovasc Diabetol* 2018;17:73.
65. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. *Cardiovasc Diabetol* 2019;18:76.
66. Singh JS, Fathi A, Vickers S, et al. Research into the effect of sodium-glucose linked transporter inhibition in left ventricular remodelling in patients with heart failure and diabetes mellitus. *Eur Heart J* 2018;Supplement 1(P905): American Diabetes Association meeting, Orlando. Available from: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-1-Chronic-heart-failure-Treatment/177516-research-into-the-effect-of-sodium-glucose-linked-transporter-inhibition-in-left-ventricular-remodelling-in-patients-with-heart-failure-and-diabetes-mellitus. [Last accessed on 16 Nov 2020]
67. Bonora BM, Vigili de Kreutzgenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. *Cardiovasc Diabetol* 2019;18:106.
68. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG outcome trial? *Diabetes Care* 2016;39:e212-3.
69. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERtugliflozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV). *Am Heart J* 2018;206:11-23.
70. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *New Engl J Med* 2020;383:1425-35.
71. Sakai T, Miura S. Abstract 17041: effect of sodium-glucose cotransporter 2 inhibitor on vascular endothelial function and diastolic function in patients with heart failure with preserved ejection fraction (hfpef). *Circulation* 2017;136:A17041. Available from: https://www.ahajournals.org/doi/10.1161/circ.136.suppl_1.17041. [Last accessed on 16 Nov 2020]
72. Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, et al. Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection fraction in diabetic patients: a multicenter randomized-controlled trial. ESC Congress 2019. Available from: https://esc365.escardio.org/Congress/ESC-Congress-2019/New-treatment-studies-in-heart-failure/196088-drug-effect-of-luseogliflozin-and-voglibose-on-heart-failure-with-preserved-ejection-fraction-in-diabetic-patients-a-multicenter-randomized-controlled-trial#abstract(Abstract: 1407). [Last accessed on 16 Nov 2020]
73. U.S. Food and Drug Administration. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. Postmarket Drug Safety Information for Patients and Providers 2020. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/sodium-glucose-cotransporter-2-sglt2-inhibitors. [Last accessed on 16 Nov 2020]
74. Ida S, Kaneko R, Imataka K, et al. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. *Heart Fail Rev* 2020; doi: 10.1007/s10741-020-09936-w.
75. Zhang DP, Xu L, Wang LJ, Wang HJ, Jiang F. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis. *Cardiovasc Diabetol* 2020;19:10.
76. Expert Panel on Cardiac Imaging, White RD, Kirsch J, Bolen MA, Battle JC, Brown RKJ, et al. ACR Appropriateness Criteria (A) Suspected New-Onset and Known Nonacute Heart Failure. *J Am Coll Radiol* 2018;15:S418-31.
77. Pieske B, Tschoppe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur heart J* 2019;40:3297-317.
78. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation* 2018;138:861-70.
79. Reddy YNV, Borlaug BA. Response by reddy and borlaug to letters regarding article, “a simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction”. *Circulation* 2019;139:992-3.
80. Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive techniques. *JACC Cardiovasc Imaging* 2020;13:245-57.

81. Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. *Am J Manag Care* 2018;24:S138-45.

82. Chetrit M, Cremer PC, Klein AL. Imaging of diastolic dysfunction in community-based epidemiological studies and randomized controlled trials of HFpEF. *JACC Cardiovasc Imaging* 2020;13:310-26.

83. Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. *Circulation* 2019;140:353-65.

84. Oh JK, Miranda WR, Bird JG, Kane GC, Nagueh SF. The 2016 diastolic function guideline: is it already time to revisit or revise them? *JACC Cardiovasc Imaging* 2020;13:327-35.

85. van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. *J Am Coll Cardiol* 2019;73:2756-68.

86. Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JP. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. *JAMA Int Med* 2017;177:554-60.

87. Brookes ST, Whiteley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technol Assess* 2001;5:1-56.

88. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. *J Cardiac Fail* 2017;23:628-51.

89. Das SR, Everett BM, Bircher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the american college of cardiology/society. *J Am Coll Cardiol* 2020;76:1117-45.

90. Seferovic PM, Coats AJS, Ponikowski P, et al. European society of cardiology/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. *Eur J Heart Fail* 2020;22:196-213.

91. Writing Committee M, Yancy CW, Jessup M, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. *Circulation* 2016;134:e282-93.

92. Gunawan F, Nassif ME, Partridge C, Ahmad T, Kosiborod M, Inzucchi SE. Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. *Cardiovasc Endocrinol Metab* 2020;9:56-9.

93. Zoler ML. SGLT2 Inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists. Medscape. 2020; Medscape Medical News: Conference News: ADA 2020. Available from: https://www.medscape.com/viewarticle/934107. [Last accessed on 16 Nov 2020]

94. American Diabetes Association Position Statement 10. Cardiovascular disease and risk management: standards of medical care in diabetes - 2020. *Diabetes Care* 2020;43:S111-34.

95. American Diabetes Association Position Statement 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes - 2020. *Diabetes Care* 2020;43:S37-47.

96. International Working Group for HTAA Advancement, Neumann PJ, Drummond MF, Jonsson B, Luce BR, Schwartz JS, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations? *Int J Technol Assess Health Care* 2010;26:71-81.

97. Kristensen FB, Lampe K, Chase DL, et al. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. *Int J Technol Assess Health Care* 2009;25:1-8.

98. World Health Organization. 2015 Global Survey on Health Technology Assessment by National Authorities. ISBN 978 92 4 150974 9.

99. Elbarbary M. Health technology assessment (HTA): a brief introduction of history and the current status in the field of cardiology under the economic crisis. *J Evid Based Med* 2015;8:161-4.

100. Elbarbary M. Health technology assessment (HTA) in cardiac field. *J Saudi Heart Assoc* 2010;22:77-84.

101. The International Network of Agencies for Health Technology Assessment. The Uniqueness of INAHTA INAHTA Position Statement. 2020. Available from: https://www.inahta.org/position-statements/. [Last accessed on 16 Nov 2020]

102. Yaku H, Ozasa N, Morimoto T, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan- observations from the prospective, multicenter kyoto congestive heart failure (KCHF) registry. *Circ J* 2018;82:2811-9.

103. Parissis J, Farmakis D, Triposkiadis F. Heart failure registries: how far can we go? *Euro J Heart Fail* 2016;18:626-8.

104. Bassand JP, Apenteng PN, Abar D, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. *Future Cardio* 2020; doi: 10.2217/fca-2020-0014.

105. Alhabib KF, Gnamh H, Almahmeed W, et al. Acute myocardial infarction and acute heart failure in the Middle East and North Africa: study design and pilot phase study results from the PEACE MENA registry. *PLoS One* 2020;15:e0236292.